MedTrace Logo

Clinical Trial to Assess the Efficacy and Safety of a Novel Cellulite Cream

NCT01562470 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2012-03-26

No results posted yet for this study

Summary

Study Hypothesis: That the test product will reduce thigh cellulite more that the placebo.

This will be a double-blind, placebo-controlled study involving subjects with distinctive cellulite appearance on both thighs. Subjects will apply test cream to one thigh and placebo to the other, by random allocation, and cellulite appearance will be measured at week 0, 8 and 16. Cellulite photographs will also be assessed by a (study blinded) trial researcher, who will assess cellulite appearance on a precisely-measured upper leg area. The subjects' own perception of cellulite appearance, from their diaries, will be numerically coded, and all three measures will be collated and analysed statistically.

Conditions

  • Thigh Cellulite

Interventions

OTHER

Cellulite reduction cream

1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.

Sponsors & Collaborators

  • Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

    lead NETWORK

Principal Investigators

  • Steven Traplin, MD · Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

  • Maggie Laidlaw, Ph.D. · Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-11-30
Completion
2011-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01562470 on ClinicalTrials.gov